Verastem | VSTM - Selling And Administration Expenses


Verastem reported $22.3M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Alaunos Therapeutics USD 447K 138K Mar/2026
AstraZeneca USD 5.8B 735M Jun/2026
Curis USD 2.96M 1.62M Mar/2026
Cytokinetics USD 104.4M 499K Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
Laboratory Of America USD 577.2M 26.2M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Verastem USD 22.3M 2.14M Mar/2026